Publications by authors named "Manuel R Modiano"

Claim this Profile
F
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
Darren Pan, Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Manuel R Modiano

Cancer Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Lecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, Ariel Lopez-Chavez, Robert C Doebele, Manuel R Modiano

Oncologist· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
Richard Derman, Eloy Roman, Manuel R Modiano, Maureen M Achebe, Lars L Thomsen

Am J Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Paul J Hesketh, Ian D Schnadig, Lee S Schwartzberg, Manuel R Modiano, Karin Jordan

Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Lee S Schwartzberg, Manuel R Modiano, Bernardo L Rapoport, Martin R Chasen, Cesare Gridelli

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Bernardo L Rapoport, Martin R Chasen, Cesare Gridelli, Laszlo Urban, Manuel R Modiano

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Ralph G Zinner, Coleman K Obasaju, David R Spigel, Robert W Weaver, J Thaddeus Beck, Manuel R Modiano

J Thorac Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
Johanna C Bendell, Heinz-Josef Lenz, Theresa Ryan, Bassel F El-Rayes, John L Marshall, Manuel R Modiano

Invest New Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
John R Mackey, Miguel Martin, Tadeusz Pienkowski, Janusz Rolski, Jean-Paul Guastalla, Manuel R Modiano

Lancet Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Tomasz P Srokowski, James E Liebmann, Manuel R Modiano, Gary I Cohen, Barbara Pro

Cancer· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Steven J Cohen, Mark M Zalupski, Manuel R Modiano, Paul Conkling, Yehuda Z Patt

Cancer Chemother Pharmacol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
David Loesch, F Anthony Greco, Neil N Senzer, Howard A Burris, John D Hainsworth, Manuel R Modiano

J Clin Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
Jacob M Estes, Charles A Leath, Sybilann Williams, Manuel R Modiano, Michael Sawyer

Gynecol Oncol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An educational program to increase cervical and breast cancer screening in Hispanic women: a Southwest Oncology Group study.
Lisa K Hansen, Polly Feigl, Manuel R Modiano, Jose A Lopez, Sylvia Escobedo Sluder

Cancer Nurs· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
Neal J Meropol, Robert A Somer, John Gutheil, Robert J Pelley, Manuel R Modiano

J Clin Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis